X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Holly Campbell

Holly Campbell Holly Campbell is a deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Recent Posts

NHE Data: Medicine spending grew just 1.3 percent in 2016

By Holly Campbell  |    December 12, 2017
According to new data from the National Health Expenditures (NHE), retail medicine spending grew just 1.3 percent in 2016, down from 9 percent in 2015. To put that in context, total spending for...   Read More

The Washington Post retracts PhRMA claim in opioid story

By Holly Campbell  |    October 18, 2017
Earlier this week, The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its...   Read More

Excerpts from testimony by PhRMA’s Lori Reilly

By Holly Campbell  |    October 17, 2017
Today, Lori Reilly, executive vice president for policy, research and membership at the Pharmaceutical Research and Manufacturers of America (PhRMA), testified at the U.S. Senate Committee on...   Read More

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

By Holly Campbell  |    October 12, 2017
PhRMA president and CEO Stephen J. Ubl joined Fox Business’ Maria Bartiromo on “Mornings with Maria” today to discuss bold steps the biopharmaceutical industry has taken in the last few months as...   Read More

4 things to know about the QuintilesIMS drivers of medicine spending in the U.S. report

By Holly Campbell  |    September 28, 2017
In case you missed it, a new analysis from QuintilesIMS, which draws on the Medicines Use and Spending in the U.S. — A Review of 2016 and Outlook to 2021 report and the Outlook for Global...   Read More

Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care

By Holly Campbell  |    September 21, 2017
As part of The Value Collaborative, an initiative of America’s biopharmaceutical companies, we recently hosted an event with Bloomberg about unlocking and supporting value in the future of health...   Read More

What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace

By Holly Campbell  |    September 12, 2017
This post has been updated as of 10/2/2017 A recent study published in JAMA Internal Medicine provides flawed and inaccurate estimates of the significant research and development (R&D) investments...   Read More

Helping those affected by the 2017 hurricane season

By Holly Campbell  |    August 31, 2017
This post has been updated as of 10/30/2017 to reflect relief efforts for Hurricanes Harvey, Irma and Maria. Given the unprecedented scale of the devastation and flooding caused by Hurricanes...   Read More

Video: PhRMA CEO discusses medicine costs with CNBC's Squawk Box

By Holly Campbell  |    July 31, 2017
PhRMA president and CEO Stephen J. Ubl joined Squawk Box this morning to put medicine costs and spending in context, the biopharmaceutical supply chain and policy solutions to address cost...   Read More

New data put medicine costs and spending in context

By Holly Campbell  |    June 26, 2017
We are in a new era of medicine where breakthrough science is transforming patient care and enabling us to more effectively treat chronic diseases, like cancer and diabetes, which are the biggest...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates